12 Feb JangoBio moving closer to commercialization
JangoBio is moving closer to commercialization as animal testing shows promise for the company’s stem cell therapy.
“We have, recently, tangible evidence that all of this now works,” said Bill Kohl, chief operating officer for JangoBio. “Before, we had a lot of ideas… We had some evidence, but now we have data that is actually working. We have to see where it goes, but this is huge.”
This Madison-based startup was started about three years ago. Its therapy is based on decades of research and the ideas of Craig Atwood, company CEO. Using stem cells, the therapy would regrow hormone-producing cells in the body that naturally decline as we age.
This would stabilize dozens of unbalanced hormones and lead to major health benefits, Atwood says, including a lower risk of developing cancer.
“This technology applies to everybody on Earth,” he said at a recent progress update meeting in Madison.
Sorry, the comment form is closed at this time.